

Imugene Announces Presentation Acceptance for Lead HER-2 Cancer Immunotherapy at the American Association for Cancer Research 2021 Annual Meeting

SYDNEY, Australia, 11 March 2021: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Rita Laeufle will present on the HER-Vaxx cancer immunotherapy program at the American Association for Cancer Research (AACR) 2021 Annual Meeting.

The presentation will be presented by Dr Laeufle, Imugene's Chief Medical Officer, at the Virtual AACR Annual Meeting scheduled for April, 2021.

The abstract presentation is entitled 'A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE IMMUNOTHERAPY PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION.'¹

Imugene's HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies and in Phase 1 and 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

The content of the presentation is embargoed until the start of the conference and will be made available online after the start of the meeting and on the Imugene website.

For further information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com

Follow us on Twitter [@TeamImugene](https://twitter.com/TeamImugene)
Like us on Facebook [@Imugene](https://www.facebook.com/Imugene)
Connect with us on LinkedIn [@Imugene Limited](https://www.linkedin.com/company/Imugene-Limited)

¹ACR Annual Meeting 2021 Abstract for Category: CT02 Phase II Adult Clinical Trials

A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE IMMUNOTHERAPY PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSION METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION

Interim Analysis Results

Marina Maglakelidze¹, Dinara Ryspayeva², Iurie Bulat³, Zoran Andric⁴, Ivan Nikolic⁵, Tanuj Chawla⁶, Rajnish Nagarkar⁷, Vaibhav Choudhary⁸, Giri Venkata⁹, Rajesh Kumar Singh¹⁰, Davorin Radosavljevic¹¹, Zoran Petrovic¹², Ursula Wiedermann¹³, Leslie Chong¹⁴, Nicholas J. Ede¹⁴, Rita Laeufle¹⁴, Anthony J. Good¹⁴

¹ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia

²ARENSIA Exploratory Medicine LLC, Kiev, Ukraine

³ARENSIA Exploratory Medicine Research Unit, Institute of Oncology, Chisinau, Republic of Moldova

⁴Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia

⁵Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

⁶Tata Medical Centre, Kolkata, India

⁷HCG Manavata Cancer Centre, Nashik, India

⁸HCG NCHRI Cancer Centre, Nagpur, India

⁹Victoria Hospital, Bangalore, India

¹⁰Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, Patna, India

¹¹Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

¹²Military Medical Academy, Belgrade, Serbia

¹³Medical University, Vienna, Austria

¹⁴Imugene Limited, Sydney, Australia

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer